Bocci v. Key Pharmaceuticals, Inc.

76 P.3d 669, 189 Or. App. 349, 2003 Ore. App. LEXIS 1223
CourtCourt of Appeals of Oregon
DecidedSeptember 10, 2003
DocketA9210-07050; A86556
StatusPublished
Cited by11 cases

This text of 76 P.3d 669 (Bocci v. Key Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals of Oregon primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Bocci v. Key Pharmaceuticals, Inc., 76 P.3d 669, 189 Or. App. 349, 2003 Ore. App. LEXIS 1223 (Or. Ct. App. 2003).

Opinion

*352 LANDAU, P. J.

This case is before us for a third time. Defendants Key Pharmaceuticals, Inc., Schering-Plough Corporation, and Schering Corporation (collectively Key), seek a reversal of a punitive damage award entered in 1994 in favor of cross-claim plaintiff Frederick D. Edwards, M.D. (Edwards). For the reasons set forth below, we conclude that Key is entitled to a remittitur of part of the punitive damage award or to a new trial.

The pertinent facts were set forth in this court’s original opinions, Bocci v. Key Pharmaceuticals, Inc., 158 Or App 521, 974 P2d 758 (1999) (Bocci I), vac’d and rem’d, 332 Or 39, 22 P3d 758, opinion on remand, 178 Or App 42, 35 P3d 1106 (2001) (Bocci II). We summarized those facts in Bocci II:

“Plaintiff Bocci was a long-time user of defendant Key’s prescription asthma medication Theo-Dur, a timed-release theophylline product. In October 1990, Bocci was prescribed the antibiotic ciprofloxacin for a skin rash, but failed to tell the prescribing physician that he was taking Theo-Dur. On October 27, 1990, Bocci went to an urgent care clinic where Edwards worked complaining of nausea, vomiting, and diarrhea. Edwards diagnosed gastroenteritis and sent Bocci home. Edwards did not diagnose theophyl-line toxicity, because Theo-Dur had been promoted to him as a safe drug, and he did not believe that a patient on a stable dose of the drug could develop a serious toxicity problem. Shortly after Edwards sent him home, Bocci experienced seizures and was admitted to a hospital emergency room. He was treated for theophylline toxicity. He suffered permanent brain damage from the seizures.
“Bocci sued Key and Edwards * * *. Edwards cross-claimed against Key for negligence and fraud on the ground that Key had failed to provide adequate information concerning the potential toxicity of Theo-Dur. The jury returned verdicts in favor of Bocci and Edwards against Key. The jury awarded Bocci more than $5 million in compensatory damages and $35 million in punitive damages. The jury awarded Edwards $500,000 in compensatory damages and $22[.5] million in punitive damages.”

*353 178 Or App at 45-46. The jury’s award was based on a special verdict that included findings that, on Edwards’s cross-claims against Key, the latter was negligent and had made fraudulent misrepresentations to Edwards that caused him damage. The jury further found that Key had acted with wanton disregard for the health and safety of others and had knowingly withheld from or misrepresented to the Food and Drug Administration (FDA) or prescribing physicians information known to be material and relevant to theophylline toxicity.

After trial, Key moved for a judgment notwithstanding the verdict or, in the alternative, a new trial or remittitur, making numerous arguments. One of those arguments was that the combined punitive damage awards to Bocci and Edwards were unconstitutionally excessive, in violation of the Due Process Clause of the Fourteenth Amendment to the United States Constitution. As noted in our previous opinion, Key urged the trial court to apply the criteria for examining punitive damage awards set forth in ORS 30.925(2). Key argued that the “imposition in this case of actual damages in the combined amount exceeding $5.5 million by itself serves as a significant and retributive measure” and that the amount of the compensatory damages awarded should be considered in determining excessiveness. In their responses, Edwards and Bocci each presented arguments as to why their respective punitive damage awards were constitutional. In its reply to those arguments, Key posited that the issue was

“whether, in combination, they [i.e., the punitive damage awards to Edwards and Bocci] exceed the maximum amount tolerable under the Due Process Clause because both awards are premised on the same factual basis and because the jury had before it all of the evidence pertaining to the totality of the wrongful conduct sought to be punished.”

(Emphasis added.) The trial court accepted Key’s formulation of the issue, applying the criteria set forth in ORS 30.925 to the combined awards to both Edwards and Bocci, but upheld the awards.

*354 Key appealed, arguing, among other things, that the punitive damage award was excessive. Meanwhile, Key settled with Bocci, leaving the challenge as to the award of damages to Edwards only. Key contended that the trial court should have reviewed the punitive damages award to Edwards independently of the award to Bocci. According to Key, an award of $22.5 million in punitive damages is excessive in relation to the $500,000 that the jury awarded Edwards for compensatory damages.

We affirmed the judgment by an equally divided court, with the court dividing on a question unrelated to the punitive damages issue. In a concurring opinion, Judge Riggs, then a member of this court, explained on behalf of four members of this court that he would have rejected Key’s challenge to the punitive damages award:

“Key argues for the first time on appeal that the trial court erred in failing to review the punitive damage award to Edwards independently of the punitive damage award to Bocci * * *. Not only did Key fail to preserve this issue in the trial court, but it waived any argument on this point by specifically requesting the court to review the punitive damage awards in their entirety * *

Bocci I, 158 Or App at 547 (Riggs, J., concurring).

Key petitioned for review. Meanwhile, the Oregon Supreme Court decided Parrott v. Carr Chevrolet, Inc., 331 Or 537, 17 P3d 473 (2001), in which it evaluated a punitive damages award in light of recent pertinent decisions from the United States Supreme Court, in particular, BMW of North America, Inc. v. Gore, 517 US 559, 116 S Ct 1589, 134 L Ed 2d 809 (1996). The Oregon Supreme Court remanded this case for reconsideration in light of Parrott. Bocci v. Key Pharmaceuticals, Inc., 332 Or 39, 22 P3d 758 (2001).

In Bocci II, we evaluated the punitive damages award in light of Parrott and the authorities it discussed. We expressly adopted the concurring opinion in Bocci I as to the scope of the question before us. That is, we concluded that, by specifically requesting that the trial court evaluate the punitive damages awards in their entirety, Key waived any argument that the punitive damages should have been evaluated *355 separately. Bocci II, 178 Or App at 47. We ultimately concluded that, evaluated in their entirety, the punitive damages awards were not excessive. Id. at 51. The Oregon Supreme Court denied review, and Key petitioned for a writ of certiorari.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Lithia Medford LM, Inc. v. Yovan
295 P.3d 642 (Court of Appeals of Oregon, 2012)
Strawn v. Farmers Insurance
209 P.3d 357 (Court of Appeals of Oregon, 2009)
Hamlin v. Hampton Lumber Mills, Inc.
193 P.3d 46 (Court of Appeals of Oregon, 2008)
Groth v. Hyundai Precision and Ind. Co.
149 P.3d 333 (Court of Appeals of Oregon, 2006)
Goddard v. Farmers Ins. Co. of Oregon
120 P.3d 1260 (Court of Appeals of Oregon, 2005)
Simon v. San Paolo US Holding Co., Inc.
113 P.3d 63 (California Supreme Court, 2005)
Johnson v. Ford Motor Co.
113 P.3d 82 (California Supreme Court, 2005)
Williams v. Philip Morris Inc.
92 P.3d 126 (Court of Appeals of Oregon, 2004)
Bocci v. Key Pharmaceuticals, Inc.
79 P.3d 908 (Court of Appeals of Oregon, 2003)
Waddill v. Anchor Hocking, Inc.
78 P.3d 570 (Court of Appeals of Oregon, 2003)

Cite This Page — Counsel Stack

Bluebook (online)
76 P.3d 669, 189 Or. App. 349, 2003 Ore. App. LEXIS 1223, Counsel Stack Legal Research, https://law.counselstack.com/opinion/bocci-v-key-pharmaceuticals-inc-orctapp-2003.